RP Bio Inc. (KOSDAQ:314140)
South Korea · Delayed Price · Currency is KRW 5,950.00
+270.00 (4.75%)
At close: Jul 31, 2026
RP Bio Financials Overview
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 137,354 | 136,219 | 123,967 | 151,046 | 138,109 | 114,964 |
Revenue Growth | 9.47% | 9.88% | -17.93% | 9.37% | 20.13% | 17.40% |
Gross Profit Gross Profit Growth | 14,346 | 13,812 | 7,184 | 15,560 | 17,754 | 12,912 |
Operating Income Operating Income Growth | 5,702 | 5,084 | -693.64 | 6,623 | 9,647 | 5,880 |
Net Income Net Income Growth | 5,603 | 4,682 | -907.12 | 5,437 | 4,316 | 3,813 |
Earnings Per Share EPS Growth | 647.79 | 541.31 | -105.00 | 582.00 | 606.00 | 580.00 |
EPS Growth | 328.41% | - | - | -3.96% | 4.48% | -16.43% |
| Fiscal Year | FY 2024 | FY 2023 |
|---|---|---|
| Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
Health Functional Food Health Functional Food Growth | 71,858 | 85,991 |
Medicines Medicines Growth | 51,472 | 63,891 |
Raw Materials, etc. Raw Materials, etc. Growth | 332.92 | 910.98 |
Other Other Growth | 303.2 | 252.84 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 23,037 | 14,626 | 18,836 | 12,558 | 18,304 | 7,718 |
Total Debt Total Debt Growth | 22,559 | 19,448 | 30,194 | 30,781 | 38,185 | 40,336 |
Net Cash (Debt) Net Cash Growth | 478.15 | -4,821 | -11,359 | -18,223 | -19,881 | -32,618 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | 55.28 | -557.39 | -1314.76 | -1950.62 | -2791.65 | -4962.17 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 16,462 | 12,476 | 13,524 | 10,580 | 1,155 | 9,459 |
Capital Expenditures CapEx Growth | -3,816 | -5,200 | -5,853 | -11,123 | -5,147 | -7,246 |
Free Cash Flow Free Cash Flow Growth | 12,645 | 7,276 | 7,670 | -543.31 | -3,992 | 2,213 |
Free Cash Flow Growth | 37.82% | -5.14% | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 10.44% | 10.14% | 5.79% | 10.30% | 12.86% | 11.23% |
Operating Margin | 4.15% | 3.73% | -0.56% | 4.38% | 6.98% | 5.12% |
Pretax Margin | 4.05% | 3.40% | -0.98% | 3.75% | 4.10% | 3.73% |
Profit Margin | 4.08% | 3.44% | -0.73% | 3.60% | 3.13% | 3.32% |
FCF Margin | 9.21% | 5.34% | 6.19% | -0.36% | -2.89% | 1.93% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 9.19 | 13.70 | - | 13.79 | 23.75 | - |
P/FCF Ratio | 4.08 | 8.81 | 5.71 | - | - | - |
PS Ratio | 0.38 | 0.47 | 0.35 | 0.50 | 0.74 | - |